We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.00 | 0.85% | 1,789.00 | 1,797.00 | 1,798.00 | 1,801.00 | 1,769.00 | 1,792.00 | 1,087,265 | 16:35:03 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 2.88B | 192M | 0.8685 | 20.70 | 3.98B |
From Apr 2019 to Apr 2024
TIDMHIK
RNS Number : 3791Q
Hikma Pharmaceuticals Plc
25 February 2021
Hikma Pharmaceuticals PLC - EIP Awards
LONDON, 25 February 2021: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK)
(LEI: 549300BNS685UXH4JI75) announces that the Remuneration Committee made the following conditional awards under the Hikma Pharmaceuticals PLC 2014 Executive Incentive Plan (the "EIP") to Persons Discharging Managerial Responsibility ("PDMR") of the Company.
Awards under the EIP were made on 25 February 2021 at a price of 2,525 pence per Ordinary Share (being the average price for the 30-day period prior to 31 December 2020, in accordance with the EIP rules) as follows:
Notification and public disclosure of transactions by persons discharging managerial responsibilities
Said Darwazah
Hot Features
Premium
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 34,827
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Said Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 19,830
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Sigurdur Olafsson
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 41,527
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Sigurdur Olafsson
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Sigurdur Olafsson
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 24,836
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Mazen Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 24,319
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Mazen Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 13,903
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Bassam Kanaan
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status EVP, Corporate Development and M&A
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 17,307
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Bassam Kanaan
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Bassam Kanaan
2 Reason for the notification
a) Position/status EVP, Corporate Development and M&A
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 13,378
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 17,390
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Khalid Nabilsi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Khalid Nabilsi
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 13,927
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Riad Mishlawi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status President, Injectables
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 20,285
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Riad Mishlawi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Riad Mishlawi
2 Reason for the notification
a) Position/status President, Injectables
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 17,120
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Majda Labadi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Majda Labadi
2 Reason for the notification
a) Position/status EVP, Organisational Development
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 11,205
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Majda Labadi
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Majda Labadi
2 Reason for the notification
a) Position/status EVP, Organisational Development
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 8,662
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Susan Ringdal
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status EVP, Strategic Planning and Global Affairs
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 8,813
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Susan Ringdal
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Susan Ringdal
2 Reason for the notification
a) Position/status EVP, Strategic Planning and Global Affairs
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 6,812
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Brian Hoffmann
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Brian Hoffmann
2 Reason for the notification
a) Position/status President, US Generics
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 12,119
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Brian Hoffmann
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Brian Hoffmann
2 Reason for the notification
a) Position/status President, US Generics
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 10,227
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Henriette Nielsen
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Henriette Nielsen
2 Reason for the notification
a) Position/status EVP, Business Operations
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 14,374
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Henriette Nielsen
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Henriette Nielsen
2 Reason for the notification
a) Position/status EVP, Business Operations
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 12,130
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Shahin Fesharaki
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Shahin Fesharaki
2 Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 14,972
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Shahin Fesharaki
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Shahin Fesharaki
2 Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 11,574
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Hussein Arkhagha
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Hussein Arkhagha
2 Reason for the notification
a) Position/status Chief Counsel
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element B of the 2014 Executive Incentive Plan
(EIP). Shares under Element B EIP award will
vest after 2 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 7,867
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Hussein Arkhagha
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Hussein Arkhagha
2 Reason for the notification
a) Position/status Chief Counsel
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial (Shares)
instrument, type ID Code: GB00B0LCW083
of instrument
and identification
code
b) Nature of the The Company granted the named individual above
transaction a conditional award to acquire Shares under
Element C of the 2014 Executive Incentive Plan
(EIP). Shares under Element C EIP award will
vest after 3 years.
c) Price(s) and Price(s): GBP25.25
volume(s) Volume(s): 5,245
d) Aggregated information N/A
e) Date of the transaction 25 February 2021
f) Place of the London Stock Exchange (XLON)
transaction
Peter Speirs
Company Secretary, responsible for releasing this announcement
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBBGDDRUDDGBU
(END) Dow Jones Newswires
February 25, 2021 08:00 ET (13:00 GMT)
1 Year Hikma Pharmaceuticals Chart |
1 Month Hikma Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
